Ruxolitinib Phosphate (CAS 1092939-17-7)

Application and positioning

Ruxolitinib phosphate is a selective JAK1/JAK2 inhibitor that suppresses JAK-STAT signalling, supplied as the phosphate salt. It is used in oral tablets for myelofibrosis, polycythaemia vera and steroid-refractory graft-versus-host disease. Laurand supplies it from audited Chinese production partners for pharmaceutical manufacturing and process development.

Quality and documentation

• Batch-specific Certificate of Analysis issued by the manufacturing site
• SDS/MSDS and specification sheet available on request
• Residual solvents and elemental impurities statements discussed per project
• For pharmaceutical manufacturing and R&D use only — not for direct administration

Packaging and handling

• Packed in double polyethylene-lined fibre drums; pack size confirmed at quotation
• Small quantities in sealed aluminium foil bags
• Palletised for air and sea freight; store dry, ventilated and protected from light

Related products

• Vandetanib (CAS 443913-73-3)
• Veliparib (CAS 912444-00-9)
• Veliparib dihydrochloride (CAS 912445-05-7)
• Vemurafenib (CAS 918504-65-1)
• 4-(1H-Pyrazol-4-yl)-7-[[2-(trimethylsilyl)ethoxy]methyl]-7H-pyrrolo[2,3-d]pyrimidine (CAS 941685-27-4)
• 3-Cyclopentyl-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]propanenitrile (CAS 1153949-38-2)

Specifications shown are indicative. The final specification and documentation package are confirmed with the quotation.